1. Search strategy and results Amir Kashani, et al. Circulation. 2006;114:2788-2797

2. Baseline Characteristics Amir Kashani, et al. Circulation 2006;114:2788-2797 CHD indicates coronary heart disease; DM, diabetes mellitus; PMSG, Pravastatin Multinational Study Group; SSSS, Scandinavian Simvastatin Survival Study; HPS, Heart Protection Study; and NR, not reported. Two studies randomized patients to 2 different statins. *Defined as other relevant cardiovascular diseases. †Numbers represent combined mean for statin and placebo arms of the study. ‡History of hypertension indicates patients on antihypertensive therapy at time of study inclusion. §History of DM indicates history of non– insulin-dependent DM. Represents current or former smokers. ¶History of smoking indicates cigarette smoking. #All patients had a history of angina or history of myocardial infarction. **History of hypertension and history of DM indicates treated hypertension and treated DM. ††Numbers based on table/figure in study.

3. Study Characteristics Amir Kashani, et al. Circulation 2006;114:2788-2797 NR indicates not reported *No. of patients randomized to this dose was not reported †Frequency of testing laboratory data ‡Six-wk intervals for 1 y, then 12-wk intervals. §Every 6 weeks for 15 months, then quarterly. Every 6 weeks for 18 months, then every 24 weeks.

4. Risk Difference of Various End Points Associated With Currently FDA-Approved Statins Amir Kashani, et al. Circulation 2006;114:2788-2797

5. Cerivastatin Trials Amir Kashani, et al. Circulation. 2006;114:2788-2797

6. Risk difference of FDAapproved statins vs cerivastatin Amir Kashani, et al. Circulation. 2006;114:2788-2797